Advertisement

Clinical programs for clinical research on AIDS: Description of a randomized prospective study of clindamycin versus pyrimethamine for prevention ofToxoplasma gondii infection

  • M. A. Jacobson
  • C. L. Besch
  • C. Child
  • R. Hafner
  • K. Muth
  • L. Deyton
Current Topic: Notes

Abstract

The risk of toxoplasmic encephalitis complicating AIDS appears largely limited to those HIV-infected patients with serologic evidence of pastToxoplasma gondii infection and low CD4 lymphocyte counts. The Community Programs for Clinical Research on AIDS has initiated a randomized, placebo-controlled trial to determine if clindamycin or pyrimethamine prophylactic regimens are effective and safe in preventing toxoplasmic encephalitis.

Keywords

Internal Medicine Clinical Research Encephalitis Clindamycin Lymphocyte Count 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Berger JR, Moskowitz L, Fischl M, Kelley RE Neurologic disease as the presenting manifestation of acquired immunodeficiency syndrome. Southern Medical Journal 1987, 80: 683–686.PubMedGoogle Scholar
  2. 2.
    Navia BA, Petito CK, Gold JWM, Cho ES, Jordan BD, Price RW Cerebral toxoplasmosis complicating the acquired immunodeficiency syndrome: clinical and neuropathological findings in 27 patients. Annals of Neurology 1986, 19: 224–238.PubMedGoogle Scholar
  3. 3.
    Luft BJ, Remington JS Toxoplasmosis of the central nervous system. In: Remington JS, Swartz MN (ed): Current clinical topics in infectious diseases. Volume 6. McGraw-Hill, New York, 1985, p. 315–358.Google Scholar
  4. 4.
    Wachtel M, Druand L, Fisher A, Sepe S, O'Sullivan, P: Seroprevalence of viral markers and toxoplasmosis in HIV-positive persons: comparing transmission risk group. In: Program and Abstracts of the 6th International Conference on AIDS, San Francisco, 1990, Abstract FB 435.Google Scholar
  5. 5.
    Grant IH, Gold JWM, Armstrong D: Risk of CNS toxoplasmosis in patients with acquired immune deficiency syndrome. In: Program and Abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 1986, Abstract no. 441.Google Scholar
  6. 6.
    Eliaszewicz, M, Lecomte I, De Sa M: Relation between decreasing seric CD4 lymphocyte count and outcome of toxoplasmosis in AIDS patients: a basis for primary prophylaxis. In: Program and Abstracts of the 6th International Conference on AIDS, San Francisco, 1990, Abstract ThB 481.Google Scholar
  7. 7.
    Luft BJ, Remington JS Toxoplasmic encephalitis. Journal of Infectious Diseases 1988, 157: 1–6.PubMedGoogle Scholar
  8. 8.
    Wanke C, Tuazon CU, Kovacs A, Dina T, Davis DO, Barton N, Katz D, Lunde M, Levy C, Conley FK, Lane HC, Fauci AS, Masur H Toxoplasma encephalitis in patients with acquired immune deficiency syndrome: diagnosis and response to therapy. American Journal of Tropical Medicine and Hygiene 1987, 36: 509–516.PubMedGoogle Scholar
  9. 9.
    Leport C, Raffi F, Matheron S, Katlama C, Regnier B, Saimot AG, Marche C, Vedrenne C, Viidé JL Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome: efficacy of long-term continuous therapy. American Journal of Medicine 1988, 84: 94–100.PubMedGoogle Scholar
  10. 10.
    Haverkos HW Assessment of therapy for toxoplasma encephalitis: the TE study group. American Journal of Medicine 1987, 82: 907–914.PubMedGoogle Scholar
  11. 11.
    Araujo FG, Remington JS Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrobial Agents and Chemotherapy 1974, 5: 647–651.PubMedGoogle Scholar
  12. 12.
    Israelski DM, Dannemann BR, Remington JS: Ex vivo activity of clindamycin againstToxoplasma gondii. In: Program and Abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, 1988, Abstract no. 1128.Google Scholar
  13. 13.
    Dannemann BR, Israelski DM, Remington JS Treatment of toxoplasmic encephalitis with intravenous clindamycin. Archives of Internal Medicine 1988, 148: 2477–2482.PubMedGoogle Scholar
  14. 14.
    Cohn JA, McMeeking A, Cohen W, Jacobs J, Holzman RS Evaluation of the policy of empiric treatment of suspectedToxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. American Journal of Medicine 1989, 86: 521–527.PubMedGoogle Scholar
  15. 15.
    Centers for Disease Control Revision of the CDC surveillance case definition for acquired immuno-deficiency syndrome. Morbidity and Mortality Weekly Report 1987, 36: 1S-15S.Google Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1991

Authors and Affiliations

  • M. A. Jacobson
    • 1
  • C. L. Besch
    • 2
  • C. Child
    • 1
  • R. Hafner
    • 3
  • K. Muth
    • 4
  • L. Deyton
    • 4
  1. 1.San Francisco Community Consortium on AIDS and San Francisco General HospitalSan FranciscoUSA
  2. 2.Louisiana Community AIDS Research ProgramTulane University Medical CenterNew OrleansUSA
  3. 3.AIDS DivisionThe National Institute of Allergy and Infectious DiseasesBethesdaUSA
  4. 4.Community Programs for Clinical Research on AIDSThe National Institute of Allergy and Infectious DiseasesBethesdaUSA

Personalised recommendations